478 related articles for article (PubMed ID: 27729460)
1. Antiestrogens: structure-activity relationships and use in breast cancer treatment.
Traboulsi T; El Ezzy M; Gleason JL; Mader S
J Mol Endocrinol; 2017 Jan; 58(1):R15-R31. PubMed ID: 27729460
[TBL] [Abstract][Full Text] [Related]
2. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
Howell SJ; Johnston SR; Howell A
Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.
Katzenellenbogen BS; Choi I; Delage-Mourroux R; Ediger TR; Martini PG; Montano M; Sun J; Weis K; Katzenellenbogen JA
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):279-85. PubMed ID: 11162936
[TBL] [Abstract][Full Text] [Related]
4. A Closer Look at Estrogen Receptor Mutations in Breast Cancer and Their Implications for Estrogen and Antiestrogen Responses.
Clusan L; Le Goff P; Flouriot G; Pakdel F
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33451133
[TBL] [Abstract][Full Text] [Related]
5. Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells.
Traboulsi T; El Ezzy M; Dumeaux V; Audemard E; Mader S
Oncogene; 2019 Feb; 38(7):1019-1037. PubMed ID: 30190545
[TBL] [Abstract][Full Text] [Related]
6. Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.
Peng J; Sengupta S; Jordan VC
Anticancer Agents Med Chem; 2009 Jun; 9(5):481-99. PubMed ID: 19519291
[TBL] [Abstract][Full Text] [Related]
7. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
McDaniel RE; Maximov PY; Jordan VC
Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002
[TBL] [Abstract][Full Text] [Related]
8. The AF-2 cofactor binding region is key for the selective SUMOylation of estrogen receptor alpha by antiestrogens.
Vallet A; El Ezzy M; Diennet M; Haidar S; Bouvier M; Mader S
J Biol Chem; 2023 Jan; 299(1):102757. PubMed ID: 36460099
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of selective estrogen receptor modulator activity in human breast cancer cells: identification of novel nuclear cofactors of antiestrogen-ERα complexes by interaction proteomics.
Cirillo F; Nassa G; Tarallo R; Stellato C; De Filippo MR; Ambrosino C; Baumann M; Nyman TA; Weisz A
J Proteome Res; 2013 Jan; 12(1):421-31. PubMed ID: 23170835
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines.
Top S; Vessières A; Leclercq G; Quivy J; Tang J; Vaissermann J; Huché M; Jaouen G
Chemistry; 2003 Nov; 9(21):5223-36. PubMed ID: 14613131
[TBL] [Abstract][Full Text] [Related]
11. Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.
Liu H; Park WC; Bentrem DJ; McKian KP; Reyes Ade L; Loweth JA; Schafer JM; Zapf JW; Jordan VC
J Biol Chem; 2002 Mar; 277(11):9189-98. PubMed ID: 11751902
[TBL] [Abstract][Full Text] [Related]
12. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
Marsaud V; Gougelet A; Maillard S; Renoir JM
Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
[TBL] [Abstract][Full Text] [Related]
13. Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy.
Márquez-Garbán DC; Deng G; Comin-Anduix B; Garcia AJ; Xing Y; Chen HW; Cheung-Lau G; Hamilton N; Jung ME; Pietras RJ
J Steroid Biochem Mol Biol; 2019 Oct; 193():105415. PubMed ID: 31226312
[TBL] [Abstract][Full Text] [Related]
14. Pure antiestrogens and breast cancer.
Elkak AE; Mokbel K
Curr Med Res Opin; 2001; 17(4):282-9. PubMed ID: 11922402
[TBL] [Abstract][Full Text] [Related]
15. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
Pickar JH; Komm BS
Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
[TBL] [Abstract][Full Text] [Related]
16. ERα-targeted endocrine therapy, resistance and the role of GPER.
Pepermans RA; Prossnitz ER
Steroids; 2019 Dec; 152():108493. PubMed ID: 31518595
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review.
Jameera Begam A; Jubie S; Nanjan MJ
Bioorg Chem; 2017 Apr; 71():257-274. PubMed ID: 28274582
[TBL] [Abstract][Full Text] [Related]
18. Estrogen signaling: An emanating therapeutic target for breast cancer treatment.
Saha T; Makar S; Swetha R; Gutti G; Singh SK
Eur J Med Chem; 2019 Sep; 177():116-143. PubMed ID: 31129450
[TBL] [Abstract][Full Text] [Related]
19. Nuclear and extranuclear-initiated estrogen receptor signaling crosstalk and endocrine resistance in breast cancer.
Kulkoyluoglu E; Madak-Erdogan Z
Steroids; 2016 Oct; 114():41-47. PubMed ID: 27394959
[TBL] [Abstract][Full Text] [Related]
20. Searching for an ideal SERM: Mining tamoxifen structure-activity relationships.
Price S; Bender SG; Yahn R; Till NA; Varady S; LaLonde RL
Bioorg Med Chem Lett; 2021 Nov; 52():128383. PubMed ID: 34592434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]